Death of multiple myeloma cells induced by cAMP-signaling involves downregulation of Mcl-1 via the JAK/STAT pathway

Cancer Letters

Volumn 335, Issue 2, 2013, Pages 323-331

  Follin Arbelet, Virginie ^a   Torgersen, Maria Lyngaas ^a   Naderi, Elin Hallan ^a   Misund, Kristine ^b   Sundan, Anders ^b   Blomhoff, Heidi Kiil ^a  

^a UNIVERSITY OF OSLO   (Norway)

^b NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

CAMP; JAK; Mcl 1; Multiple myeloma; STAT

Indexed keywords

CASPASE 3; CASPASE 9; CYCLIC AMP; INTERLEUKIN 6; JANUS KINASE; JANUS KINASE 1; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN MCL 1; STAT PROTEIN; STAT3 PROTEIN;

APOPTOSIS; ARTICLE; CELL DEATH; DOWN REGULATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MITOCHONDRIAL MEMBRANE POTENTIAL; MOLECULAR MECHANICS; MULTIPLE MYELOMA; MYELOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION;

APOPTOSIS; CELL LINE, TUMOR; CYCLIC AMP; DOWN-REGULATION; FORSKOLIN; HUMANS; INTERLEUKIN-6; JANUS KINASE 1; MULTIPLE MYELOMA; PROTO-ONCOGENE PROTEINS C-BCL-2; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; SYNDECAN-1;

EID: 84878225378     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.02.042     Document Type: Article

References (67)

1. Naviglio S., Caraglia M., Abbruzzese A., Chiosi E., Di G.D., Marra M., Romano M., Sorrentino A., Sorvillo L., Spina A., Illiano G. Protein kinase A as a biological target in cancer therapy. Expert. Opin. Ther. Targets 2009, 13:83-92.
2. Insel P.A., Zhang L., Murray F., Yokouchi H., Zambon A.C. Cyclic AMP is both a pro-apoptotic and anti-apoptotic second messenger. Acta Physiol. (Oxf) 2012, 204:277-287.
3. Kobsar A., Heeg S., Krohne K., Opitz A., Walter U., Bock M., Gambaryan S., Eigenthaler M. Cyclic nucleotide-regulated proliferation and differentiation vary in human hematopoietic progenitor cells derived from healthy persons, tumor patients, and chronic myelocytic leukemia patients. Stem Cells Dev. 2008, 17:81-91.
4. de R.J., Zwartkruis F.J., Verheijen M.H., Cool R.H., Nijman S.M., Wittinghofer A., Bos J.L. Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP. Nature 1998, 396:474-477.
5. Tasken K., Aandahl E.M. Localized effects of cAMP mediated by distinct routes of protein kinase A. Physiol. Rev. 2004, 84:137-167.
6. Cho-Chung Y.S., Nesterova M.V. Tumor reversion: protein kinase A isozyme switching. Ann. N.Y. Acad. Sci. 2005, 1058:76-86.
7. Monahan T.M., Marchand N.W., Fritz R.R., Abell C.W. Cyclic adenosine 3':5'-monophosphate levels and activities of related enzymes in normal and leukemic lymphocytes. Cancer Res. 1975, 35:2540-2547.
8. Wiernik P.H., Paietta E., Goloubeva O., Lee S.J., Makower D., Bennett J.M., Wade J.L., Ghosh C., Kaminer L.S., Pizzolo J., Tallman M.S. Phase II study of theophylline in chronic lymphocytic leukemia: a study of the Eastern Cooperative Oncology Group (E4998). Leukemia 2004, 18:1605-1610.
9. Lerner A., Epstein P.M. Cyclic nucleotide phosphodiesterases as targets for treatment of haematological malignancies. Biochem. J. 2006, 393:21-41.
10. Rickles R.J., Pierce L.T., Giordano T.P., Tam W.F., McMillin D.W., Delmore J., Laubach J.P., Borisy A.A., Richardson P.G., Lee M.S. Adenosine A2A receptor agonists and PDE inhibitors: a synergistic multitarget mechanism discovered through systematic combination screening in B-cell malignancies. Blood 2010, 116:593-602.
11. Mahindra A., Laubach J., Raje N., Munshi N., Richardson P.G., Anderson K. Latest advances and current challenges in the treatment of multiple myeloma. Nat. Rev. Clin. Oncol. 2012, 9:135-143.
12. Follin-Arbelet V., Hofgaard P.O., Hauglin H., Naderi S., Sundan A., Blomhoff R., Bogen B., Blomhoff H.K. Cyclic AMP induces apoptosis in multiple myeloma cells and inhibits tumor development in a mouse myeloma model. BMC Cancer 2011, 11:301.
13. Derenne S., Monia B., Dean N.M., Taylor J.K., Rapp M.J., Harousseau J.L., Bataille R., Amiot M. Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells. Blood 2002, 100:194-199.
14. Zhang B., Gojo I., Fenton R.G. Myeloid cell factor-1 is a critical survival factor for multiple myeloma. Blood 2002, 99:1885-1893.
15. Willis S.N., Chen L., Dewson G., Wei A., Naik E., Fletcher J.I., Adams J.M., Huang D.C. Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev. 2005, 19:1294-1305.
16. Yang-Yen H.F. Mcl-1: a highly regulated cell death and survival controller. J. Biomed. Sci. 2006, 13:201-204.
17. Beroukhim R., Mermel C.H., Porter D., Wei G., Raychaudhuri S., Donovan J., Barretina J., Boehm J.S., Dobson J., Urashima M., Mc Henry K.T., Pinchback R.M., Ligon A.H., Cho Y.J., Haery L., Greulich H., Reich M., Winckler W., Lawrence M.S., Weir B.A., Tanaka K.E., Chiang D.Y., Bass A.J., Loo A., Hoffman C., Prensner J., Liefeld T., Gao Q., Yecies D., Signoretti S., Maher E., Kaye F.J., Sasaki H., Tepper J.E., Fletcher J.A., Tabernero J., Baselga J., Tsao M.S., Demichelis F., Rubin M.A., Janne P.A., Daly M.J., Nucera C., Levine R.L., Ebert B.L., Gabriel S., Rustgi A.K., Antonescu C.R., Ladanyi M., Letai A., Garraway L.A., Loda M., Beer D.G., True L.D., Okamoto A., Pomeroy S.L., Singer S., Golub T.R., Lander E.S., Getz G., Sellers W.R., Meyerson M. The landscape of somatic copy-number alteration across human cancers. Nature 2010, 463:899-905.
18. Cho-Vega J.H., Rassidakis G.Z., Admirand J.H., Oyarzo M., Ramalingam P., Paraguya A., McDonnell T.J., Amin H.M., Medeiros L.J. MCL-1 expression in B-cell non-Hodgkin's lymphomas. Hum. Pathol. 2004, 35:1095-1100.
19. Fleischer B., Schulze-Bergkamen H., Schuchmann M., Weber A., Biesterfeld S., Muller M., Krammer P.H., Galle P.R. Mcl-1 is an anti-apoptotic factor for human hepatocellular carcinoma. Int. J. Oncol. 2006, 28:25-32.
20. Wuilleme-Toumi S., Robillard N., Gomez P., Moreau P., Le G.S., Avet-Loiseau H., Harousseau J.L., Amiot M., Bataille R. Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival. Leukemia 2005, 19:1248-1252.
21. Le G.S., Podar K., Harousseau J.L., Anderson K.C. Mcl-1 regulation and its role in multiple myeloma. Cell Cycle 2004, 3:1259-1262.
22. Jourdan M., Veyrune J.L., De V.J., Redal N., Couderc G., Klein B. A major role for Mcl-1 antiapoptotic protein in the IL-6-induced survival of human myeloma cells. Oncogene 2003, 22:2950-2959.
23. Klein B., Zhang X.G., Jourdan M., Boiron J.M., Portier M., Lu Z.Y., Wijdenes J., Brochier J., Bataille R. Interleukin-6 is the central tumor growth factor in vitro and in vivo in multiple myeloma. Eur. Cytokine Netw. 1990, 1:193-201.
24. Kawano M., Hirano T., Matsuda T., Taga T., Horii Y., Iwato K., Asaoku H., Tang B., Tanabe O., Tanaka H., Kuramoto A., Kishimoto T. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 1988, 332:83-85.
25. Yu H., Pardoll D., Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat. Rev. Cancer 2009, 9:798-809.
26. Levy D.E., Inghirami G. STAT3: a multifaceted oncogene. Proc. Natl. Acad. Sci. USA 2006, 103:10151-10152.
27. Bharti A.C., Shishodia S., Reuben J.M., Weber D., Alexanian R., Raj-Vadhan S., Estrov Z., Talpaz M., Aggarwal B.B. Nuclear factor-kappaB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis. Blood 2004, 103:3175-3184.
28. Buettner R., Mora L.B., Jove R. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin. Cancer Res. 2002, 8:945-954.
29. Schuringa J.J., Wierenga A.T., Kruijer W., Vellenga E. Constitutive Stat3, Tyr705, and Ser727 phosphorylation in acute myeloid leukemia cells caused by the autocrine secretion of interleukin-6. Blood 2000, 95:3765-3770.
30. Darzynkiewicz Z., Bruno S., Del B.G., Gorczyca W., Hotz M.A., Lassota P., Traganos F. Features of apoptotic cells measured by flow cytometry. Cytometry 1992, 13:795-808.
31. Seamon K.B., Padgett W., Daly J.W. Forskolin: unique diterpene activator of adenylate cyclase in membranes and in intact cells. Proc. Natl. Acad. Sci. USA 1981, 78:3363-3367.
32. Youle R.J., Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat. Rev. Mol. Cell Biol. 2008, 9:47-59.
33. Laurenza A., Sutkowski E.M., Seamon K.B. Forskolin: a specific stimulator of adenylyl cyclase or a diterpene with multiple sites of action?. Trends Pharmacol. Sci. 1989, 10:442-447.
34. Ono K., Fozzard H.A., Hanck D.A. A direct effect of forskolin on sodium channel bursting. Pflugers Arch. 1995, 429:561-569.
35. Coleman R.A., Smith W.L., Narumiya S. International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacol. Rev. 1994, 46:205-229.
36. Negishi M., Sugimoto Y., Ichikawa A. Prostanoid receptors and their biological actions. Prog. Lipid Res. 1993, 32:417-434.
37. Adams K.W., Cooper G.M. Rapid turnover of mcl-1 couples translation to cell survival and apoptosis. J. Biol. Chem. 2007, 282:6192-6200.
38. Thomas L.W., Lam C., Edwards S.W. Mcl-1; the molecular regulation of protein function. FEBS Lett. 2010, 584:2981-2989.
39. Puthier D., Bataille R., Amiot M. IL-6 up-regulates mcl-1 in human myeloma cells through JAK/STAT rather than ras/MAP kinase pathway. Eur. J. Immunol. 1999, 29:3945-3950.
40. Imada K., Leonard W.J. The Jak-STAT pathway. Mol. Immunol. 2000, 37:1-11.
41. Teoh G., Anderson K.C. Interaction of tumor and host cells with adhesion and extracellular matrix molecules in the development of multiple myeloma. Hematol. Oncol. Clin. North Am. 1997, 11:27-42.
42. Schwab G., Siegall C.B., Aarden L.A., Neckers L.M., Nordan R.P. Characterization of an interleukin-6-mediated autocrine growth loop in the human multiple myeloma cell line, U266. Blood 1991, 77:587-593.
43. Westendorf J.J., Ahmann G.J., Greipp P.R., Witzig T.E., Lust J.A., Jelinek D.F. Establishment and characterization of three myeloma cell lines that demonstrate variable cytokine responses and abilities to produce autocrine interleukin-6. Leukemia 1996, 10:866-876.
44. Lonial S., Mitsiades C.S., Richardson P.G. Treatment options for relapsed and refractory multiple myeloma. Clin. Cancer Res. 2011, 17:1264-1277.
45. Krett N.L., Zell J.L., Halgren R.G., Pillay S., Traynor A.E., Rosen S.T. Cyclic adenosine-3',5'-monophosphate-mediated cytotoxicity in steroid sensitive and resistant myeloma. Clin. Cancer Res. 1997, 3:1781-1787.
46. Gandhi V., Ayres M., Halgren R.G., Krett N.L., Newman R.A., Rosen S.T. 8-chloro-cAMP and 8-chloro-adenosine act by the same mechanism in multiple myeloma cells. Cancer Res. 2001, 61:5474-5479.
47. Halgren R.G., Traynor A.E., Pillay S., Zell J.L., Heller K.F., Krett N.L., Rosen S.T. 8Cl-cAMP cytotoxicity in both steroid sensitive and insensitive multiple myeloma cell lines is mediated by 8Cl-adenosine. Blood 1998, 92:2893-2898.
48. Aggarwal B.B., Sethi G., Ahn K.S., Sandur S.K., Pandey M.K., Kunnumakkara A.B., Sung B., Ichikawa H. Targeting signal-transducer-and-activator-of-transcription-3 for prevention and therapy of cancer: modern target but ancient solution. Ann. N.Y. Acad. Sci. 2006, 1091:151-169.
49. Kiuchi N., Nakajima K., Ichiba M., Fukada T., Narimatsu M., Mizuno K., Hibi M., Hirano T. STAT3 is required for the gp130-mediated full activation of the c-myc gene. J. Exp. Med. 1999, 189:63-73.
50. Niu G., Wright K.L., Huang M., Song L., Haura E., Turkson J., Zhang S., Wang T., Sinibaldi D., Coppola D., Heller R., Ellis L.M., Karras J., Bromberg J., Pardoll D., Jove R., Yu H. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 2002, 21:2000-2008.
51. Bourguignon L.Y., Earle C., Wong G., Spevak C.C., Krueger K. Stem cell marker (Nanog) and Stat-3 signaling promote MicroRNA-21 expression and chemoresistance in hyaluronan/CD44-activated head and neck squamous cell carcinoma cells. Oncogene 2012, 31:149-160.
52. Zhong Z., Wen Z., Darnell J.E. Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science 1994, 264:95-98.
53. Monaghan K.A., Khong T., Burns C.J., Spencer A. The novel JAK inhibitor CYT387 suppresses multiple signalling pathways, prevents proliferation and induces apoptosis in phenotypically diverse myeloma cells. Leukemia 2011, 25:1891-1899.
54. Raje N., Kumar S., Hideshima T., Roccaro A., Ishitsuka K., Yasui H., Shiraishi N., Chauhan D., Munshi N.C., Green S.R., Anderson K.C. Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma. Blood 2005, 106:1042-1047.
55. Rhee Y.H., Jeong S.J., Lee H.J., Lee H.J., Koh W., Jung J.H., Kim S.H., Sung-Hoon K. Inhibition of STAT3 signaling and induction of SHP1 mediate antiangiogenic and antitumor activities of ergosterol peroxide in U266 multiple myeloma cells. BMC Cancer 2012, 12:28.
56. Scuto A., Krejci P., Popplewell L., Wu J., Wang Y., Kujawski M., Kowolik C., Xin H., Chen L., Wang Y., Kretzner L., Yu H., Wilcox W.R., Yen Y., Forman S., Jove R. The novel JAK inhibitor AZD1480 blocks STAT3 and FGFR3 signaling, resulting in suppression of human myeloma cell growth and survival. Leukemia 2011, 25:538-550.
57. Akgul C. Mcl-1 is a potential therapeutic target in multiple types of cancer. Cell Mol. Life Sci. 2009, 66:1326-1336.
58. Chao J.R., Wang J.M., Lee S.F., Peng H.W., Lin Y.H., Chou C.H., Li J.C., Huang H.M., Chou C.K., Kuo M.L., Yen J.J., Yang-Yen H.F. Mcl-1 is an immediate-early gene activated by the granulocyte-macrophage colony-stimulating factor (GM-CSF) signaling pathway and is one component of the GM-CSF viability response. Mol. Cell Biol. 1998, 18:4883-4898.
59. Munshi N.C., Hideshima T., Carrasco D., Shammas M., Auclair D., Davies F., Mitsiades N., Mitsiades C., Kim R.S., Li C., Rajkumar S.V., Fonseca R., Bergsagel L., Chauhan D., Anderson K.C. Identification of genes modulated in multiple myeloma using genetically identical twin samples. Blood 2004, 103:1799-1806.
60. Caligaris-Cappio F., Gregoretti M.G., Merico F., Gottardi D., Ghia P., Parvis G., Bergui L. Bone marrow microenvironment and the progression of multiple myeloma. Leukemia Lymphoma 1992, 8:15-22.
61. Frassanito M.A., Cusmai A., Iodice G., Dammacco F. Autocrine interleukin-6 production and highly malignant multiple myeloma: relation with resistance to drug-induced apoptosis. Blood 2001, 97:483-489.
62. Gasperini S., Crepaldi L., Calzetti F., Gatto L., Berlato C., Bazzoni F., Yoshimura A., Cassatella M.A. Interleukin-10 and cAMP-elevating agents cooperate to induce suppressor of cytokine signaling-3 via a protein kinase A-independent signal. Eur. Cytokine Netw. 2002, 13:47-53.
63. Sands W.A., Woolson H.D., Milne G.R., Rutherford C., Palmer T.M. Exchange protein activated by cyclic AMP (Epac)-mediated induction of suppressor of cytokine signaling 3 (SOCS-3) in vascular endothelial cells. Mol. Cell Biol. 2006, 26:6333-6346.
64. Valdés L.J., Mislankar S.G., Paul A.G. Coleus barbatus (C. forskohlii) (Lamiaceae) and the Potential New Drug Forskolin (Coleonol). Econom. Bot. 1987, 41:474-483.
65. Kikura M., Morita K., Sato S. Pharmacokinetics and a simulation model of colforsin daropate, new forskolin derivative inotropic vasodilator, in patients undergoing coronary artery bypass grafting. Pharmacol. Res. 2004, 49:275-281.
66. Godard M.P., Johnson B.A., Richmond S.R. Body composition and hormonal adaptations associated with forskolin consumption in overweight and obese men. Obes. Res. 2005, 13:1335-1343.
67. Huerta M., Urzua Z., Trujillo X., Gonzalez-Sanchez R., Trujillo-Hernandez B. Forskolin compared with beclomethasone for prevention of asthma attacks: a single-blind clinical trial. J. Int. Med. Res. 2010, 38:661-668.